Vasodilator therapy for chronic congestive heart failure.
D002216:Captopril / Q000009:adverse effects / Q000627:therapeutic use; D006328:Cardiac Catheterization; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006760:Hospitalization; D006801:Humans; D006830:Hydralazine / Q000009:adverse effects / Q000627:therapeutic use; D009200:Myocardial Contraction / Q000187:drug effects; D009566:Nitrates / Q000009:adverse effects / Q000627:therapeutic use; D005996:Nitroglycerin / Q000627:therapeutic use; D011224:Prazosin / Q000009:adverse effects / Q000627:therapeutic use; D011312:Pressure; D014655:Vascular Resistance / Q000187:drug effects; D014665:Vasodilator Agents / Q000145:classification / Q000627:therapeutic use*; D014680:Veins / Q000187:drug effects
D009566:Nitrates; D014665:Vasodilator Agents; D006830:Hydralazine; D002216:Captopril; D005996:Nitroglycerin; D011224:Prazosin